Hem › Esophageal adenocarcinom › Nevada › Reno
Kliniska studier för Esophageal adenocarcinom i Reno, NV
3 studier för Esophageal adenocarcinom söker deltagare vid platser i och runt Reno (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
RekryterarFas 2/3
- Renown Regional Medical Center, Reno
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
RekryterarFas 3
- Renown Regional Medical Center, Reno
- Saint Mary's Regional Medical Center, Reno
- Carson Tahoe Regional Medical Center, Carson City · 25 mi bort
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
RekryterarFas 2/3
- Renown Health Medical Oncology, Reno
- Renown Office of Clinical Research, Reno
- Renown Regional Medical Center, Reno
Esophageal adenocarcinom-studier i andra städer
- New York City, NY18 studier
- Boston, MA13 studier
- Houston, TX12 studier
- Nashville, TN11 studier
- Arlington, VA11 studier
- Durham, NC10 studier
- Rochester, MN9 studier
- Baldwin Park, CA9 studier
- St. Louis, MO9 studier
- Jacksonville, FL9 studier
- Queens, NY9 studier
- Los Angeles, CA9 studier
Andra studier i Reno
- Icke-småcellig lungcancer16 studier
- Bröstcancer13 studier
- Lungcancer9 studier
- Makuladegeneration8 studier
- Geografisk atrofi8 studier
- Äggstockscancer7 studier
- Cancer (alla typer)7 studier
- Akut myeloid leukemi5 studier
- Bukspottkörtelcancer5 studier
- Metastaserande cancer5 studier
- Tjocktarmscancer5 studier
- Kolorektal cancer5 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.